Early Diagnosis for Ocular Ischemia Syndrome Using Arterial Spin Labeling Magnetic Resonance Imaging Technique

Early Diagnosis for Ocular Ischemia Syndrome Using Arterial Spin Labeling Magnetic Resonance Imaging Technique: a Prospective Multicenter Cohort Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03863171

Enrollment

190

Registered

2019-03-05

Start date

2019-03-01

Completion date

2021-03-01

Last updated

2019-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Ischemia Syndrome

Brief summary

1. To evaluate ocular blood perfusion status and the possibility of craniocerebral vascular lesions of patients with ocular ischemia syndrome (OIS) using arterial spin labeling (ASL) magnetic resonance imaging technique. 2. To evaluate the specificity, sensitivity and accuracy of arterial spin labeling (ASL) magnetic resonance imaging technique in OIS diagnosis, compared with the traditional routine examination method.

Interventions

DIAGNOSTIC_TESTArterial spin labeling (ASL) magnetic resonance imaging

Arterial spin labeling (ASL) magnetic resonance imaging test

DIAGNOSTIC_TESTFundus fluorescein angiography

Fundus fluorescein angiography test

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 80 Years

Inclusion criteria

* Ocular ischemia syndrome group: Patients diagnosed with ocular ischemia syndrome; * Age-related macular degeneration group (Control group): Patients diagnosed with age-related macular degeneration; * Age: 50-80 years; * Sex: all; * Patients signed written informed consent.

Exclusion criteria

* Fundus fluorescein angiography (FFA) clear images cannot be obtained due to refractive media problems(such as corneal leukoplakia, severe cataract, vitreous hemorrhage, etc.) ; * Patients with contraindications for FFA; * Patients was unable to perform magnetic resonance rmaging (MRI) test; * Patients with history of bleeding and cerebral infarction; * Patients with a history of surgery within 3 months; * Patients who had participated in other clinical trials within 3 months; * Patients who disagree and refuse to participate in the trial.

Design outcomes

Primary

Measure	Time frame	Description
Blood Flow (BF)	through study completion, an average of 2 years	Blood Flow (BF)：a parameter measured by arterial spin labeling perfusion MRI to qualify the perfusion in tissue-specific units (ml blood/gram tissue/time)

Countries

China

Contacts

Primary ContactYanling Wang, MD

wangyanling999@vip.sina.com+86-13701277114

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026